GLPG1690
Sponsors
Galapagos NV
Conditions
HealthyIdiopathic Pulmonary FibrosisSystemic Sclerosis
Phase 1
Study to Assess Bioavailability of GLPG1690 Given as Oral Capsule or Tablet
CompletedNCT03143712
Start: 2017-04-18End: 2017-06-14Updated: 2017-06-20
A Study in Healthy Male Volunteers to Look at How the Test Medicine GLPG1690 is Taken up by the Body When Doses of Itraconazole and Voriconazole Are Given to Healthy Volunteers
CompletedNCT03515382
Start: 2018-03-16End: 2018-06-01Updated: 2018-06-11
Phase 2
A Clinical Study to Test How Effective and Safe GLPG1690 is for Participants With Systemic Sclerosis
CompletedNCT03798366
Start: 2019-01-14End: 2020-06-22Updated: 2021-05-04
A Clinical Study to Test Long Term Safety of GLPG1690 for Patients With Systemic Sclerosis
TerminatedNCT03976648
Start: 2019-07-18End: 2021-04-13Updated: 2022-03-29
Phase 3
A Clinical Study to Test How Effective and Safe GLPG1690 is for Subjects With Idiopathic Pulmonary Fibrosis (IPF) When Used Together With Standard of Care
TerminatedNCT03711162
Start: 2018-11-28End: 2021-03-30Updated: 2022-07-29
A Clinical Study to Test How Effective and Safe GLPG1690 is for Participants With Idiopathic Pulmonary Fibrosis (IPF) When Used Together With Standard of Care
TerminatedNCT03733444
Start: 2018-11-05End: 2021-03-30Updated: 2022-07-29